Cargando…
Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors
Peptides derived from the C-terminal heptad repeat (CHR) region of HIV-1 gp41 is potent viral membrane fusion inhibitors, such as the first clinically approved peptide drug T20 and a group of newly-designed peptides. The resistance profiles of various HIV-1 fusion inhibitors were previously characte...
Autores principales: | Yu, Danwei, Su, Yang, Ding, Xiaohui, Zhu, Yuanmei, Qin, Bo, Chong, Huihui, Cui, Sheng, He, Yuxian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150849/ https://www.ncbi.nlm.nih.gov/pubmed/32197300 http://dx.doi.org/10.3390/v12030326 |
Ejemplares similares
-
Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors
por: Geng, Xiuzhu, et al.
Publicado: (2019) -
Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus
por: Yu, Danwei, et al.
Publicado: (2021) -
Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity
por: Zhu, Yuanmei, et al.
Publicado: (2020) -
SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses
por: Zhu, Yuanmei, et al.
Publicado: (2021) -
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants
por: Yu, Danwei, et al.
Publicado: (2021)